A Phase 1 interventional study of Remzistotug and Dostarlimab in Neoplasms, sponsored by GlaxoSmithKline. Active, not recruiting at 26 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's enrollment of 152 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
Histological or cytological documentation of loco-regionally recurrent solid tumors where curative treatment options have been exhausted, or solid tumors; types as follows:
Exclusion Criteria:
Prior treatment with the following therapies (specified time periods are from last dose of prior treatment to first dose of study intervention):
Toxicity from previous anticancer treatment, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Remzistotug
Drug: Remzistotug · Drug: Dostarlimab
Drug: Remzistotug · Drug: Dostarlimab · Drug: Belrestotug
Drug: Dostarlimab · Drug: Belrestotug
Drug: Remzistotug · Drug: Dostarlimab · Drug: Belrestotug
Drug: Dostarlimab · Drug: Belrestotug · Drug: Nelistotug
Drug: Dostarlimab
Drug: Dostarlimab · Drug: GSK5764227
Remzistotug will be administered.
Dostarlimab will be administered.
Belrestotug will be administered.
Nelistotug will be administered.
GSK5764227 will be administered.
Arms A, B, C, I: Number of Participants with dose-limiting toxicities (DLTs)
Time frame: Up to 21 days
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Up to 27 months
Number of Participants With Clinically Significant Changes in Laboratory Parameters, Electrocardiogram (ECG) and Vital Signs
Time frame: Up to 24 months
Number of Participants With Dose Reductions or Delays
Time frame: Up to 24 months
Number of Participants With Withdrawals due to AEs
Number of participants with adverse events leading to permanent discontinuation of study treatment or withdrawal from study by overall frequency will be assessed.
Time frame: Up to 27 months
Overall Response Rate (ORR)
Objective response rate will be calculated as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. It is defined as the percentage of participants with a best overall confirmed complete response (CR) or partial response (PR) at any time as per disease-specific criteria.
Time frame: Up to 24 months
Number of Participants With Positive Antidrug Antibodies (ADA) to remzistotug
Time frame: Up to 27 months
Titres of ADA to remzistotug
Time frame: Up to 27 months
Number of Participants With Positive ADA to Dostarlimab
Time frame: Up to 27 months
Titers of ADA to Dostarlimab
Time frame: Up to 27 months
Number of Participants With Positive ADA to belrestotug
Time frame: Up to 27 months
Titers of ADA to belrestotug
Time frame: Up to 27 months
Number of Participants With Positive ADA to nelistotug
Time frame: Up to 27 months
Titers of ADA to nelistotug
Time frame: Up to 27 months
Number of Participants With Positive ADA to GSK5764227
Time frame: Up to 27 months
Titers of ADA to GSK5764227
Time frame: Up to 27 months
Serum Concentrations of remzistotug
Time frame: Up to 4 months
Serum Concentrations of dostarlimab
Time frame: Up to 4 months
Serum Concentrations of belrestotug
Time frame: Up to 4 months
Serum Concentrations of nelistotug
Time frame: Up to 4 months
Serum Concentrations of GSK5764227
Time frame: Up to 4 months
Maximum Observed Plasma Concentration (Cmax) of remzistotug Monotherapy
Time frame: Up to 27 months
Cmax of remzistotug in Combination With Dostarlimab
Time frame: Up to 27 months
Cmax of remzistotug in Combination With dostarlimab and belrestotug
Time frame: Up to 27 months
Cmax following administration of dostarlimab with belrestotug
Time frame: Up to 27 months
Minimum Observed Plasma Concentration (Cmin) of remzistotug Monotherapy
Time frame: Up to 27 months
Cmin of remzistotug in Combination With Dostarlimab
Time frame: Up to 27 months
Cmin of remzistotug in Combination With dostarlimab and belrestotug
Time frame: Up to 27 months
Cmin following administration of dostarlimab with belrestotug
Time frame: Up to 27 months
Area Under the Plasma Concentration Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) of remzistotug
Time frame: Up to 27 months
AUC(0-t) of remzistotug in Combination With Dostarlimab
Time frame: Up to 27 months
AUC(0-t) of remzistotug in Combination With dostarlimab and belrestotug
Time frame: Up to 27 months
AUC(0-t) following administration of dostarlimab with belrestotug
Time frame: Up to 27 months
AUC From Time Zero to Infinity (AUC[0-infinity]) of Single Dosing of remzistotug
Time frame: Up to 27 months
AUC(0-infinity) of Single Dosing of remzistotug in Combination with Dostarlimab
Time frame: Up to 27 months
AUC(0-infinity) of Single Dosing of remzistotug in Combination With dostarlimab and belrestotug
Time frame: Up to 27 months
AUC(0-infinity) of Single Dosing of remzistotug following administration of dostarlimab with belrestotug
Time frame: Up to 27 months
Cmax of dostarlimab in Combination With remzistotug
Time frame: Up to 27 months
Cmax of dostarlimab in combination with GSK5764227
Time frame: Up to 27 months
Cmax of dostarlimab in combination with remzistotug and belrestotug
Time frame: Up to 27 months
Cmax of dostarlimab in combination with belrestotug
Time frame: Up to 27 months
Cmax of dostarlimab in combination with belrestotug and remzistotug
Time frame: Up to 27 months
Cmax of dostarlimab in combination with belrestotug and nelistotug
Time frame: Up to 27 months
China cohort: Cmax of dostarlimab monotherapy
Time frame: Up to 18 months
Cmin of dostarlimab in Combination With remzistotug
Time frame: Up to 27 months
Cmin of dostarlimab in combination with GSK5764227
Time frame: Up to 18 months
Cmin of dostarlimab in combination with remzistotug and belrestotug
Time frame: Up to 27 months
Cmin of dostarlimab in combination with belrestotug
Time frame: Up to 27 months
Cmin of dostarlimab in combination with belrestotug and remzistotug
Time frame: Up to 27 months
Cmin of dostarlimab in combination with belrestotug and nelistotug
Time frame: Up to 27 months
China cohort: Cmin of dostarlimab monotherapy
Time frame: Up to 18 months
AUC(0-t) of dostarlimab in Combination With remzistotug
Time frame: Up to 27 months
AUC(0-t) of dostarlimab in combination with GSK5764227
Time frame: Up to 18 months
AUC(0-t) of dostarlimab in combination with remzistotug and belrestotug
Time frame: Up to 27 months
AUC(0-t) of dostarlimab in combination with belrestotug
Time frame: Up to 27 months
AUC(0-t) of dostarlimab in combination with belrestotug and remzistotug
Time frame: Up to 27 months
AUC(0-t) of dostarlimab in combination with belrestotug and nelistotug
Time frame: Up to 27 months
China cohort: AUC(0-t) of dostarlimab monotherapy
Time frame: Up to 18 months
AUC(0-infinity) of dostarlimab in Combination With remzistotug
Time frame: Up to 27 months
AUC(0-infinity) of dostarlimab in combination with GSK5764227
Time frame: Up to 27 months
AUC(0-infinity) of dostarlimab in combination with remzistotug and belrestotug
Time frame: Up to 27 months
AUC(0-infinity) of dostarlimab in combination with belrestotug
Time frame: Up to 27 months
AUC(0-infinity) of dostarlimab in combination with belrestotug and remzistotug
Time frame: Up to 27 months
AUC(0-infinity) of dostarlimab in combination with belrestotug and nelistotug
Time frame: Up to 27 months
China cohort: AUC(0-infinity) of dostarlimab monotherapy
Time frame: Up to 18 months
T1/2 of dostarlimab in Combination With remzistotug
Time frame: Up to 27 months
T1/2 of dostarlimab in combination with GSK5764227
Time frame: Up to 18 months
China cohort: T1/2 of dostarlimab monotherapy
Time frame: Up to 18 months
Cmax of belrestotug in combination with dostarlimab and belrestotug
Time frame: Up to 27 months
Cmax of belrestotug in combination with dostarlimab
Time frame: Up to 27 months
Cmax of belrestotug in combination with dostarlimab and remzistotug
Time frame: Up to 27 months
Cmax of belrestotug in combination with dostarlimab and nelistotug
Time frame: Up to 27 months
Cmin of belrestotug in combination with dostarlimab and belrestotug
Time frame: Up to 27 months
Cmin of belrestotug in combination with dostarlimab
Time frame: Up to 27 months
Cmin of belrestotug in combination with dostarlimab and remzistotug
Time frame: Up to 27 months
Cmin of belrestotug in combination with dostarlimab and nelistotug
Time frame: Up to 27 months
AUC (0-t) of belrestotug in combination with dostarlimab and belrestotug
Time frame: Up to 27 months
AUC (0-t) of belrestotug in combination with dostarlimab
Time frame: Up to 27 months
AUC (0-t) of belrestotug in combination with dostarlimab and remzistotug
Time frame: Up to 27 months
AUC (0-t) of belrestotug in combination with dostarlimab and nelistotug
Time frame: Up to 27 months
AUC (0-infinity) of belrestotug in combination with dostarlimab and belrestotug
Time frame: Up to 27 months
AUC (0- infinity) of belrestotug in combination with dostarlimab
Time frame: Up to 27 months
AUC (0- infinity) of belrestotug in combination with dostarlimab and remzistotug
Time frame: Up to 27 months
AUC (0- infinity) of belrestotug in combination with dostarlimab and nelistotug
Time frame: Up to 27 months
Cmax of nelistotug in combination with dostarlimab and belrestotug
Time frame: Up to 27 months
Cmin of nelistotug in combination with dostarlimab and belrestotug
Time frame: Up to 27 months
AUC (0-t) of nelistotug in combination with dostarlimab and belrestotug
Time frame: Up to 27 months
AUC (0-infinity) of nelistotug in combination with dostarlimab and belrestotug
Time frame: Up to 27 months
Cmax of GSK5764227 in combination with dostarlimab
Time frame: Up to 18 months
Cmin of GSK5764227 in combination with dostarlimab
Time frame: Up to 18 months
AUC (0-t) of GSK5764227 conjugated Ab in combination with dostarlimab
Time frame: Up to 18 months
AUC (0-t) of GSK5764227 small molecule toxin in combination with dostarlimab
Time frame: Up to 18 months
AUC (0-infinity) of GSK5764227 conjugated Ab in combination with dostarlimab
Time frame: Up to 18 months
AUC (0-infinity) of GSK5764227 small molecule toxin in combination with dostarlimab
Time frame: Up to 18 months
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Mar 2022 to primary completion in Jun 2026, 51 months.
Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 51 months is above that.
Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2027 → Jun 2026, on Oct 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Belrestotug · Nelistotug · Risvutatug rezetecan